585 related articles for article (PubMed ID: 29944670)
1. Supervised learning reveals circulating biomarker levels diagnostic of hepatocellular carcinoma in a clinically relevant model of non-alcoholic steatohepatitis; An OAD to NASH.
Hwang A; Shi C; Zhu E; Naaz F; Zhou P; Rasheed Z; Liu M; Jung LS; Duan B; Li J; Jiang K; Paka L; Gadhiya SV; Dana D; Ali Q; Yamin MA; Goldberg ID; Narayan P
PLoS One; 2018; 13(6):e0198937. PubMed ID: 29944670
[TBL] [Abstract][Full Text] [Related]
2. Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma.
Vongsuvanh R; van der Poorten D; Iseli T; Strasser SI; McCaughan GW; George J
PLoS One; 2016; 11(5):e0155800. PubMed ID: 27219517
[TBL] [Abstract][Full Text] [Related]
3. Plasma osteopontin is a biomarker for the severity of alcoholic liver cirrhosis, not for hepatocellular carcinoma screening.
Simão A; Madaleno J; Silva N; Rodrigues F; Caseiro P; Costa JN; Carvalho A
BMC Gastroenterol; 2015 Jun; 15():73. PubMed ID: 26122937
[TBL] [Abstract][Full Text] [Related]
4. Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma.
Koyama N; Yamazaki T; Kanetsuki Y; Hirota J; Asai T; Mitsumoto Y; Mizuno M; Shima T; Kanbara Y; Arai S; Miyazaki T; Okanoue T
J Gastroenterol; 2018 Jun; 53(6):770-779. PubMed ID: 29086016
[TBL] [Abstract][Full Text] [Related]
5. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis.
Best J; Bechmann LP; Sowa JP; Sydor S; Dechêne A; Pflanz K; Bedreli S; Schotten C; Geier A; Berg T; Fischer J; Vogel A; Bantel H; Weinmann A; Schattenberg JM; Huber Y; Wege H; von Felden J; Schulze K; Bettinger D; Thimme R; Sinner F; Schütte K; Weiss KH; Toyoda H; Yasuda S; Kumada T; Berhane S; Wichert M; Heider D; Gerken G; Johnson P; Canbay A
Clin Gastroenterol Hepatol; 2020 Mar; 18(3):728-735.e4. PubMed ID: 31712073
[TBL] [Abstract][Full Text] [Related]
6. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study.
Shen Q; Fan J; Yang XR; Tan Y; Zhao W; Xu Y; Wang N; Niu Y; Wu Z; Zhou J; Qiu SJ; Shi YH; Yu B; Tang N; Chu W; Wang M; Wu J; Zhang Z; Yang S; Gu J; Wang H; Qin W
Lancet Oncol; 2012 Aug; 13(8):817-26. PubMed ID: 22738799
[TBL] [Abstract][Full Text] [Related]
7. The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma.
Lewinska M; Santos-Laso A; Arretxe E; Alonso C; Zhuravleva E; Jimenez-Agüero R; Eizaguirre E; Pareja MJ; Romero-Gómez M; Arrese M; Suppli MP; Knop FK; Oversoe SK; Villadsen GE; Decaens T; Carrilho FJ; de Oliveira CP; Sangro B; Macias RIR; Banales JM; Andersen JB
EBioMedicine; 2021 Nov; 73():103661. PubMed ID: 34740106
[TBL] [Abstract][Full Text] [Related]
8. The Serum Oxidative/Anti-oxidative Stress Balance Becomes Dysregulated in Patients with Non-alcoholic Steatohepatitis Associated with Hepatocellular Carcinoma.
Shimomura Y; Takaki A; Wada N; Yasunaka T; Ikeda F; Maruyama T; Tamaki N; Uchida D; Onishi H; Kuwaki K; Nakamura S; Nouso K; Miyake Y; Koike K; Tomofuji T; Morita M; Yamamoto K; Okada H
Intern Med; 2017; 56(3):243-251. PubMed ID: 28154266
[TBL] [Abstract][Full Text] [Related]
9. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease.
Beale G; Chattopadhyay D; Gray J; Stewart S; Hudson M; Day C; Trerotoli P; Giannelli G; Manas D; Reeves H
BMC Cancer; 2008 Jul; 8():200. PubMed ID: 18638391
[TBL] [Abstract][Full Text] [Related]
10. TEMs but not DKK1 could serve as complementary biomarkers for AFP in diagnosing AFP-negative hepatocellular carcinoma.
Mao L; Wang Y; Wang D; Han G; Fu S; Wang J
PLoS One; 2017; 12(9):e0183880. PubMed ID: 28902891
[TBL] [Abstract][Full Text] [Related]
11. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Osteopontin as a Biomarker in Hepatocellular Carcinomas in Egyptian Patients with Chronic HCV Cirrhosis.
Abdel-Hafiz SM; Hamdy HE; Khorshed FM; Aboushousha TS; Safwat G; Saber MA; Seleem M; Soliman AH
Asian Pac J Cancer Prev; 2018 Apr; 19(4):1021-1027. PubMed ID: 29693976
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma.
Ge T; Shen Q; Wang N; Zhang Y; Ge Z; Chu W; Lv X; Zhao F; Zhao W; Fan J; Qin W
Med Oncol; 2015 Mar; 32(3):59. PubMed ID: 25652109
[TBL] [Abstract][Full Text] [Related]
14. OPN is a promising serological biomarker for hepatocellular carcinoma diagnosis.
Zhu M; Zheng J; Wu F; Kang B; Liang J; Heskia F; Zhang X; Shan Y
J Med Virol; 2020 Dec; 92(12):3596-3603. PubMed ID: 32043608
[TBL] [Abstract][Full Text] [Related]
15. Significance of plasma osteopontin in diagnosis of hepatitis C virus-related hepatocellular carcinoma.
Nabih MI; Aref WM; Fathy MM
Arab J Gastroenterol; 2014; 15(3-4):103-7. PubMed ID: 25249230
[TBL] [Abstract][Full Text] [Related]
16. Long-term prognostic impact of osteopontin and Dickkopf-related protein 1 in patients with hepatocellular carcinoma after hepatectomy.
Byeon H; Lee SD; Hong EK; Lee DE; Kim BH; Seo Y; Joo J; Han SS; Kim SH; Park SJ
Pathol Res Pract; 2018 Jun; 214(6):814-820. PubMed ID: 29753515
[TBL] [Abstract][Full Text] [Related]
17. Glycopeptide Biomarkers in Serum Haptoglobin for Hepatocellular Carcinoma Detection in Patients with Nonalcoholic Steatohepatitis.
Zhu J; Huang J; Zhang J; Chen Z; Lin Y; Grigorean G; Li L; Liu S; Singal AG; Parikh ND; Lubman DM
J Proteome Res; 2020 Aug; 19(8):3452-3466. PubMed ID: 32412768
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice.
Yokohama K; Fukunishi S; Ii M; Nakamura K; Ohama H; Tsuchimoto Y; Asai A; Tsuda Y; Higuchi K
Int J Mol Med; 2016 Nov; 38(5):1499-1506. PubMed ID: 28025996
[TBL] [Abstract][Full Text] [Related]
19. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
20. Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma.
Liu X; Chi X; Gong Q; Gao L; Niu Y; Chi X; Cheng M; Si Y; Wang M; Zhong J; Niu J; Yang W
PLoS One; 2015; 10(5):e0127518. PubMed ID: 25996938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
